| Literature DB >> 22018212 |
Rohina Rubicz1, Charles T Leach, Ellen Kraig, Nikhil V Dhurandhar, Barry Grubbs, John Blangero, Robert Yolken, Harald Hh Göring.
Abstract
BACKGROUND: Infection risks vary among individuals and between populations. Here we present information on the seroprevalence of 13 common infectious agents in a San Antonio-based sample of Mexican Americans. Mexican Americans represent the largest and most rapidly growing minority population in the U.S., and they are also considered a health disparities population.Entities:
Year: 2011 PMID: 22018212 PMCID: PMC3214184 DOI: 10.1186/1756-0500-4-433
Source DB: PubMed Journal: BMC Res Notes ISSN: 1756-0500
Participant characteristics
| Characteristic | Value (percent) |
|---|---|
| Sex | |
| Male | 482 (39.3%) |
| Female | 745 (60.7%) |
| Age | |
| Age range | 15-94 years |
| Mean age | 39 years |
| Education* | |
| Elementary school (1-8 years) | 329 (27.9%) |
| Some high school (9-11 years) | 324 (27.5%) |
| High school graduation (12 years) | 370 (31.4%) |
| Some college (> 12 years) | 157 (13.3%) |
| Monthly Household Income† | |
| Under $500 | 181 (16.2%) |
| $500-$749 | 159 (14.2%) |
| $750-$999 | 143 (12.8%) |
| $1000-$1249 | 171 (15.3%) |
| $1250-$1499 | 117 (10.5%) |
| $1500-$1999 | 123 (11.0%) |
| $2000-$2999 | 127 (11.4%) |
| $3000 and above | 95 (8.5%) |
| Residence | |
| Texas | 1211(98.7%) |
| Other US location | 16 (1.3%) |
*Information available for 1180 participants
†Information available for 1116 participants
Seroprevalence by sex and age
| Sex and Age | count | CMV | EBV | HSV-1 | HSV-2 | HHV-6 | VZV | Ad- 36 | HAV | IA | IB | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Females | ||||||||||||||
| < 20 | 71 | 84.5 | 31.0 | 1.4 | 26.8 | 40.8 | 80.3 | 7.0 | 93.0 | 95.8 | 14.1 | 32.4 | 77.5 | 60.6 |
| 20-29 | 188 | 85.1 | 49.5 | 8.5 | 38.3 | 46.3 | 78.2 | 17.6 | 87.8 | 92.6 | 12.8 | 63.3 | 71.3 | 51.6 |
| 30-39 | 149 | 83.9 | 53.7 | 6.0 | 63.8 | 47.0 | 83.2 | 21.5 | 81.9 | 91.9 | 13.4 | 78.5 | 69.1 | 56.4 |
| 40-49 | 165 | 81.2 | 60.0 | 6.1 | 72.1 | 42.4 | 82.4 | 32.1 | 75.8 | 88.5 | 10.9 | 81.2 | 73.9 | 52.7 |
| 50-59 | 86 | 93.0 | 72.1 | 11.6 | 76.7 | 47.7 | 86.0 | 34.9 | 74.4 | 91.9 | 16.3 | 95.3 | 69.8 | 46.5 |
| 60-69 | 49 | 77.6 | 79.6 | 16.3 | 75.5 | 36.7 | 83.7 | 44.9 | 67.3 | 85.7 | 20.4 | 98.0 | 85.7 | 69.4 |
| ≥70 | 37 | 81.1 | 81.1 | 27.0 | 91.9 | 35.1 | 89.2 | 37.8 | 64.9 | 97.3 | 18.9 | 86.5 | 89.2 | 59.5 |
| subtotal | 745 | 84.2 | 57.0 | 8.6 | 59.3 | 44.0 | 82.1 | 25.4 | 80.4 | 91.5 | 13.8 | 74.5 | 73.7 | 54.6 |
| Males | ||||||||||||||
| < 20 | 75 | 88.0 | 32.0 | 4.0 | 28.0 | 45.3 | 69.3 | 5.3 | 90.7 | 94.7 | 10.7 | 29.3 | 81.3 | 62.7 |
| 20-29 | 122 | 81.1 | 45.9 | 2.5 | 32.8 | 54.1 | 78.7 | 13.1 | 93.4 | 92.6 | 17.2 | 59.8 | 78.7 | 62.3 |
| 30-39 | 85 | 84.7 | 67.1 | 10.6 | 52.9 | 47.1 | 82.4 | 21.2 | 84.7 | 88.2 | 14.1 | 78.8 | 80.0 | 68.2 |
| 40-49 | 89 | 92.1 | 67.4 | 9.0 | 61.8 | 56.2 | 87.6 | 13.5 | 75.3 | 95.5 | 14.6 | 86.5 | 80.9 | 62.9 |
| 50-59 | 56 | 89.3 | 67.9 | 19.6 | 64.3 | 35.7 | 85.7 | 16.1 | 78.6 | 91.1 | 5.4 | 91.1 | 83.9 | 44.6 |
| 60-69 | 29 | 100 | 65.5 | 17.2 | 75.9 | 48.3 | 82.8 | 27.6 | 72.4 | 100 | 13.8 | 96.6 | 86.2 | 58.6 |
| ≥70 | 26 | 100 | 84.6 | 38.5 | 73.1 | 65.4 | 88.5 | 38.5 | 61.5 | 96.2 | 3.8 | 92.3 | 84.6 | 76.9 |
| subtotal | 482 | 88.0 | 57.3 | 10.2 | 49.4 | 50.0 | 81.1 | 16.0 | 83.4 | 93.2 | 12.9 | 71.0 | 81.1 | 62.0 |
| Overall | 1227 | 85.7 | 57.1 | 9.2 | 55.4 | 46.4 | 81.7 | 21.7 | 81.6 | 92.2 | 13.4 | 73.1 | 76.6 | 57.5 |
Cp = C. pneumoniae; Hp = H. pylori; Tg = T. gondii; IA = Influenza A; IB = Influenza B
Predictors of serostatus
| Pathogen | Location | Sex | Age | Education | Income |
|---|---|---|---|---|---|
| 0.242 (0.023) | -0.007 (0.021) | 0.108 (0.095) | 0.066 (0.238) | ||
| -0.032 (0.832) | 0.057 (0.454) | 0.120 (0.005) | |||
| 0.000 (0.998) | 0.106 (0.315) | 0.120 (0.054) | |||
| CMV | -0.291 (0.072) | -0.181 (0.021) | -0.011 (0.809) | 0.020 (0.647) | |
| EBV | 0.151 (0.066) | 0.001 (0.693) | -0.002 (0.970) | 0.034 (0.447) | |
| HSV-1 | -0.008 (0.925) | 0.090 (0.084) | 0.106 (0.029) | ||
| HSV-2 | 0.128 (0.350) | 0.011 (0.822) | 0.098 (0.033) | ||
| HHV-6 | 0.194 (0.065) | -0.118 (0.039) | |||
| VZV | 0.230 (0.387) | 0.150 (0.407) | 0.000 (0.956) | -0.071 (0.519) | -0.181 (0.077) |
| Ad-36 | -0.359 (0.011) | -0.048 (0.607) | 0.000 (0.991) | 0.023 (0.671) | 0.131 (0.010) |
| HAV | -0.024 (0.770) | 0.132 (0.014) | 0.062 (0.179) | ||
| Influenza A | 0.149 (0.412) | 0.206 (0.045) | -0.005 (0.117) | -0.087 (0.154) | -0.083 (0.143) |
| Influenza B | 0.128 (0.136) | 0.003 (0.267) | -0.075 (0.147) | -0.014 (0.769) |
All p-values in bold remain statistically significant after correcting for multiple testing across 13 pathogens using a conservative Sidàk correction.
* Analysis of location compares 147 individuals in Mexico with 1,227 participants in the U.S. All remaining analyses presented in this table refer only to the 1,227 U.S. participants. Positive regression coefficient refers to higher seroprevalence in the U.S. compared to Mexico (e.g., HHV-6 seroprevalence is higher for U.S. participants).
†Positive regression coefficient relates to a higher frequency in males compared to females (e.g., C. pneumoniae seroprevalence is higher in males).
Serostatus is a discrete trait, and since we used a liability threshold model for analysis of such dichotomous traits within a variance components model for analysis of family data [29], the direction of effect of the predictor on the pathogen is opposite of the sign of the regression coefficient (e.g., H. pylori seroprevalence decreases with higher education).
Figure 1Seroprevalence of human herpesviruses by age (sliding 15-year age windows used to smooth the curves, and age shown is the midpoint of each age interval).
Figure 2Seroprevalence of miscellaneous pathogens by age (sliding 15-year age windows used to smooth the curves, and age shown is the midpoint of each age interval.)
Figure 3Number of seropositive reactions to infectious agents for each study participant.
Seroprevalence comparisons with published studies
| Pathogens | Seroprevalence rates | Seroprevalence |
|---|---|---|
| 86 | 63 (Brooklyn, NY, USA) [ | |
| 57 | 62 (Mexican American)* [ | |
| 9 | 25 (Mexican American)* [ | |
| CMV | 55 | 85 (Mexican American)* [ |
| EBV | 46 | 73-90 (general U.S. adult population) [ |
| HSV-1 | 82 | 88 (Mexican American)* [ |
| HSV-2 | 22 (total) | 38 (Mexican American women)* [ |
| HHV-6 | 82 | 60-70 [ |
| VZV | 92 | 97(Mexican American)* [ |
| Ad-36 | 13 | 11 (non-obese) [ |
| HAV | 73 | 82 (Mexican American)* [ |
* NHANES III data